2024 CUDA丨Dr. Sujun Han: Prostate Cancer Quality Control Indicators Aid in Standardizing Diagnosis and Treatment, Enhancing Both Survival and Quality

2024 CUDA丨Dr. Sujun Han: Prostate Cancer Quality Control Indicators Aid in Standardizing Diagnosis and Treatment, Enhancing Both Survival and Quality

Prostate cancer is the most common malignancy of the male genitourinary system. Compared to Western countries, a larger proportion of prostate cancer patients in China are diagnosed at intermediate to advanced stages, leading to poorer prognosis. At the recent 2024 Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA), Urology Frontier invited Dr. Sujun Han from the National Cancer Center/Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, to discuss the background of the development of single-disease quality control indicators for prostate cancer, the value of promoting standardized diagnosis and treatment, and treatment strategies for advanced patients, with the goal of improving both survival rates and quality of life for prostate cancer patients.
2024 CUDA丨Dr. Nianzeng Xing: Special Sessions Propel New Productivity in Urology, Highlighting the Spirit of International Collaboration in Healthcare

2024 CUDA丨Dr. Nianzeng Xing: Special Sessions Propel New Productivity in Urology, Highlighting the Spirit of International Collaboration in Healthcare

In the journey toward a "Healthy China," urology leads the way. From August 9th to 11th, 2024, the eagerly anticipated 2024 Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association was grandly held in Xi'an. With a broad global perspective, the conference showcased the latest achievements in the field of urology from multiple angles, paving the way for a new chapter in China's healthcare construction alongside urology professionals nationwide. After the event, Urology Frontier had the honor of interviewing the conference chairman, Dr. Nianzeng Xing, Vice President of the Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, who shared insights on the conference highlights, Chinese initiatives, and the training of young professionals.
2024 COMB丨Dr. Songqing Ye: Exploring the Development of CDK4/6 Inhibitors, ADCs, and Immunotherapy in Early-Stage Breast Cancer

2024 COMB丨Dr. Songqing Ye: Exploring the Development of CDK4/6 Inhibitors, ADCs, and Immunotherapy in Early-Stage Breast Cancer

From August 2-4, 2024, the 7th Oncology Precision Diagnosis and Treatment Conference and the 10th Breast Cancer Individualized Treatment Conference (COMB), organized by the China Cancer Foundation and Beijing Breast Disease Prevention Society, was grandly held in Beijing. The conference brought together the latest advances in individualized precision treatment for breast cancer in China, providing a broad platform for promoting new concepts, developing new technologies, and creating new models in the breast cancer field. With the recent advancements in breast cancer precision medicine, CDK4/6 inhibitors (CDK4/6i), immunotherapy drugs, and antibody-drug conjugates (ADCs) have significantly improved the survival benefits for breast cancer patients. Oncology Frontier conducted an exclusive interview with Dr. Songqing Ye from Fujian Provincial Hospital to discuss the current landscape and trends in the development of new drugs for precision treatment of early-stage breast cancer.
2024 COMB丨Dr. Yanxia Zhao: Comprehensive Considerations for Radiotherapy Exemption and Hypofractionated Radiotherapy in Clinical Practice

2024 COMB丨Dr. Yanxia Zhao: Comprehensive Considerations for Radiotherapy Exemption and Hypofractionated Radiotherapy in Clinical Practice

From August 2-4, 2024, the 7th Oncology Precision Diagnosis and Treatment Conference and the 10th Breast Cancer Individualized Treatment Conference (COMB), organized by the China Cancer Foundation and Beijing Breast Disease Prevention Society, was grandly held in Beijing. The conference gathered the latest advancements in individualized precision treatment for breast cancer in China and provided insights into the precise implementation of postoperative radiotherapy for breast cancer. At the event, Oncology Frontier invited Dr. Yanxia Zhao from Union Hospital, Tongji Hospital of Huazhong University of Science and Technology, to interpret the standards for exempting radiotherapy post-surgery, analyze the advantages of hypofractionated radiotherapy, and share tips on managing radiotherapy-related complications.
AIDS Interview | Enhancing Immune Protection for HIV-Positive Individuals: Tailored Vaccination Strategies

AIDS Interview | Enhancing Immune Protection for HIV-Positive Individuals: Tailored Vaccination Strategies

In the field of AIDS prevention and treatment, tailored immunization strategies for HIV-positive individuals are becoming crucial for improving patients' quality of life and prolonging their lifespan. At the 25th International AIDS Conference (AIDS 2024), Dr. Anna Maria Geretti from the Institute of Infection and Global Health, University of Liverpool presented an insightful report on this topic and subsequently engaged in an extensive interview with " Infectious Disease Frontier"(IIDF). She emphasized the importance of ensuring that HIV-positive individuals receive appropriate vaccination recommendations and pointed out the deficiencies in comprehensiveness and personalization in current guidelines. Dr. Geretti elaborated on the key factors to consider when formulating personalized vaccination strategies, such as immune status, viral load, and CD4+ T-cell count, which directly influence vaccine selection and effectiveness. Furthermore, she shared the latest research findings and vaccination recommendations for vaccines against hepatitis B, shingles, pneumococcal disease, and human papillomavirus (HPV), providing a more scientific and comprehensive protection plan for HIV-positive individuals.
AIDS Interview | Doxycycline Pre-Exposure Prophylaxis Shows Significant Effects in Preventing STIs Among HIV-Positive Individuals

AIDS Interview | Doxycycline Pre-Exposure Prophylaxis Shows Significant Effects in Preventing STIs Among HIV-Positive Individuals

At the 25th International AIDS Conference, a study led by Dr. Troy Grennan from the British Columbia University and the Canadian Centre for Disease Control revealed the astonishing effectiveness of doxycycline pre-exposure prophylaxis (DoxyPrEP) in reducing the incidence of bacterial sexually transmitted infections (STIs) among HIV-positive men who have sex with men. The study found that taking 100 mg of doxycycline daily significantly reduced the incidence of syphilis, chlamydia infection, and gonorrhea, with an overall reduction rate of up to 80%. This breakthrough discovery not only provides a new strategy for STI prevention but also offers important evidence for future public health policy formulation. With the advancement of larger-scale clinical trials, doxycycline is expected to become an important tool in the field of STI prevention, contributing to global public health security. " Infectious Disease Frontier"（IIDF） invited Dr. Troy Grennan for an exclusive interview.
Dr. Mark Muthiah: Exploration of Liver Fibrosis Reversal and Patient Clinical Management

Dr. Mark Muthiah: Exploration of Liver Fibrosis Reversal and Patient Clinical Management

Recently, the Combined GlHep&SHC 2024 was held in Singapore. This conference brings together elite scholars in the field of liver disease from around the world to discuss the latest developments, challenges, and opportunities in liver disease. Hepatology Digest invited Dr. Mark Muthiah from the National University Hospital, Singapore to conduct in-depth discussions on issues related to liver fibrosis and patient clinical management. The following is a transcript of the interview.
Dr Ken Liu: New Technology for Hepatocellular Carcinoma Detection

Dr Ken Liu: New Technology for Hepatocellular Carcinoma Detection

The Combined GlHep&SHC 2024 was recently held in Singapore. This conference brings together elite scholars in the field of liver disease from around the world to discuss the latest developments, challenges, and opportunities in liver disease. Liver cancer is the third leading cause of cancer death worldwide, and hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for 90% of all liver cancers. During the conference, our magazine invited Dr Ken Liu from the Royal Prince Alfred Hospital in Australia to conduct an exclusive interview on HCC related issues.
International Lung Cancer Conferenc | Dr. Huijuan Wang Reviews Perioperative Treatment Advances in NSCLC

International Lung Cancer Conferenc | Dr. Huijuan Wang Reviews Perioperative Treatment Advances in NSCLC

The perioperative treatment of early-stage non-small cell lung cancer (NSCLC) has now entered the era of precision-targeted therapy and immunotherapy. At the NSCLC Medical Treatment Session of the International Lung Cancer Conference (CLC 2024) held from August 9-11, Dr. Huijuan Wang from Henan Cancer Hospital delivered a keynote speech titled "Advances in Perioperative Treatment of NSCLC." This article provides a brief overview of the content of her presentation.